These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27882656)

  • 21. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
    Schmidt DM; McCafferty DG
    Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
    Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
    Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
    Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A
    Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.
    Zheng YC; Duan YC; Ma JL; Xu RM; Zi X; Lv WL; Wang MM; Ye XW; Zhu S; Mobley D; Zhu YY; Wang JW; Li JF; Wang ZR; Zhao W; Liu HM
    J Med Chem; 2013 Nov; 56(21):8543-60. PubMed ID: 24131029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
    Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
    Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone H3 peptide based LSD1-selective inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
    Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
    Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
    Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
    Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trans-2-phenylcyclopropylamine regulates zebrafish lateral line neuromast development mediated by depression of LSD1 activity.
    He Y; Yu H; Sun S; Wang Y; Liu I; Chen Z; Li H
    Int J Dev Biol; 2013; 57(5):365-73. PubMed ID: 23873368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity.
    Ourailidou ME; Lenoci A; Zwergel C; Rotili D; Mai A; Dekker FJ
    Bioorg Med Chem; 2017 Feb; 25(3):847-856. PubMed ID: 27989416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
    Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
    Hamada S; Suzuki T; Mino K; Koseki K; Oehme F; Flamme I; Ozasa H; Itoh Y; Ogasawara D; Komaarashi H; Kato A; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
    J Med Chem; 2010 Aug; 53(15):5629-38. PubMed ID: 20684604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
    Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
    Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing.
    Li Z; Qin T; Li Z; Zhao X; Zhang X; Zhao T; Yang N; Miao J; Ma J; Zhang Z
    Eur J Med Chem; 2021 Dec; 225():113778. PubMed ID: 34416665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.